NATHAN VOLLBRECHT: Open Payments
NPI 1932893591 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,807 in 158 payments from 21 companies in 2025. Trend: 2023 $411 · 2024 $164 · 2025 $2,807
Food & beverage: $2,805Education: $2
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $480 |
| Vanda Pharmaceuticals Inc. | 16 | $380 |
| Corium, LLC | 13 | $325 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $292 |
| Lundbeck LLC | 10 | $197 |
| Collegium Pharmaceutical, Inc. | 13 | $178 |
| Otsuka America Pharmaceutical, Inc. | 16 | $170 |
| Supernus Pharmaceuticals, Inc. | 8 | $159 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| Alkermes, Inc. | 4 | $85 |
Products named: VRAYLAR, FANAPT, REXULTI, Azstarys, CAPLYTA, Jornay PM, Qelbree, LYBALVI.
Industry payments across AZ — which companies pay providers there.
